|
| Status |
Public on May 30, 2017 |
| Title |
Human basal-like breast cancer cell line HCC1143 treated with BET inhibitor JQ1 in combination with MEK inhibitor Trametinib or PI3K/mTOR inhibitor BEZ235 |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
The goal of this experiment was to understand the changes in gene expression in the human basal-like breast cancer cell line HCC1143 following treatment with the MEK inhibitor Trametinib (T), PI3K/mTOR inhibitor BEZ235 (B), the BET inhibition JQ1 (JQ), Trametinib + JQ1 (TJ), or BEZ235 + JQ1(BJ), compared to a DMSO control (D). Samples were treated for 72hr and run in triplicate.
|
| |
|
| Overall design |
The human basal-like breast cancer cell line HCC1143 was treated for 72hr with 1uM Trametinib (T), 1uM BEZ235, 1uM JQ1 (JQ), 1uM Trametinib + 1uM JQ1 (TJ), 1uM BEZ235 + 1uM JQ1 (BJ), or a 0.05% DMSO control. Total RNA was isolated using a QIAGEN total RNA RNeasy kit, libraries were generated with a Truseq kit, and samples were run on the Nextseq500, data processing is described below.
|
| |
|
| Contributor(s) |
Risom T, Sears RC |
| Citation(s) |
30232459 |
| |
| Submission date |
May 30, 2016 |
| Last update date |
Jul 25, 2021 |
| Contact name |
Tyler Risom |
| E-mail(s) |
tyler.risom@gmail.com
|
| Organization name |
Oregon Health & Science University
|
| Department |
Molecular Medical Genetics
|
| Lab |
Dr. Rosalie Sears
|
| Street address |
2730 SW Moody Ave
|
| City |
Portland |
| State/province |
Oregon |
| ZIP/Postal code |
97201 |
| Country |
USA |
| |
|
| Platforms (2) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
| Samples (21)
|
|
| Relations |
| BioProject |
PRJNA323723 |
| SRA |
SRP075882 |
Less...
More...